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Single-domain Variable New Antigen Receptors (VNARs) from the immune system of sharks
are the smallest naturally occurring binding domains found in nature. Possessing flexible
paratopes that can recognize protein motifs inaccessible to classical antibodies, VNARs have
yet to be exploited for the development of SARS-CoV-2 therapeutics. Here, we detail
the identification of a series of VNARs from a VNAR phage display library screened against
the SARS-CoV-2 receptor binding domain (RBD). The ability of the VNARs to neutralize
pseudotype and authentic live SARS-CoV-2 virus rivalled or exceeded that of full-length
immunoglobulins and other single-domain antibodies. Crystallographic analysis of two
VNARs found that they recognized separate epitopes on the RBD and had distinctly different
mechanisms of virus neutralization unique to VNARs. Structural and biochemical data sug-
gest that VNARs would be effective therapeutic agents against emerging SARS-CoV-2
mutants, including the Delta variant, and coronaviruses across multiple phylogenetic lineages.
This study highlights the utility of VNARs as effective therapeutics against coronaviruses and
may serve as a critical milestone for nearing a paradigm shift of the greater biologic
landscape.
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The COVID-19 pandemic caused by the severe acuterespiratory syndrome coronavirus 2 (SARS-CoV-2) hasresulted in a devastating global health crisis. Though vac-
cines are the centrepiece for controlling the pandemic, the ben-
efits of vaccines depend upon complex population vaccination
strategies that remain vulnerable to manufacturing or deployment
delays. The widely implemented two-dose requirement to achieve
efficacy, leaves the possibility of non-compliance for the second
dose, a situation that may be exacerbated further by the decision
in certain areas to extend the time interval between dosing. The
rapid evolution of SARS-CoV-2 into highly infectious variants
across the globe also has the potential to impact vaccine efficacy.
Researchers have reported that the new SARS-CoV-2 variants can
result in reduced sensitivity to antibody therapies, convalescent
plasma, and vaccine sera1–4. It has been documented that people
with compromised immune systems respond poorly to COVID-
19 vaccines, thus necessitating the development of additional
antiviral therapeutics5,6. As we enter the next key stage in our
global escape plan from this pandemic, it is vital to develop
alternative therapeutic approaches and, concurrently, expand our
knowledge of this virus.
Neutralizing antibody (NAb) therapeutics that block virus
entry into the host cell have demonstrated efficacy at treating
COVID-19 infection. Two NAb therapeutics (LY3819253 and
REGN-COV2) received emergency use authorization status from
the Food and Drug Administration for use in the clinic7. SARS-
CoV-2 NAbs target the trimeric spike (S) protein on the viral
surface that mediates cell entry. The S protein has two distinct
functional subunits that facilitate cell attachment (S1) and fusion
of the viral and host cell membranes (S2). The receptor-binding
domain (RBD) on the S1 subunit is responsible for engaging
angiotensin-converting enzyme 2 (ACE2)—the cognate receptor
required for membrane fusion. The RBD exists in two different
conformations; the closed “down” conformation and the open
“up” conformation which is highly accessible to ACE2. Studies
with NAbs that target the RBD have revealed mechanisms of
viral neutralization based on changes in the “up” and “down”
conformations. In general, NAbs act by blocking the ACE2
binding interface or by trapping the RBD in the unstable “up”
conformation. Complicating the development of effective NAbs
is the emergence of new SARS-CoV-2 variants with highly
mutated S proteins. Studies have shown that mutational changes
in the RBD observed in the variants correspond to surface-
exposed residues within or proximal to the ACE2 binding
interface. These mutations can result in the modification of NAb
epitopes leading to attenuated or abrogated neutralization of the
virus by antibodies. Thus, there is a need for NAbs that can
recognize cryptic epitopes inaccessible to human antibodies that
are impervious to mutational drift.
Variable New Antigen Receptors (VNARs) represent an
unexplored technology for the development of next-generation
NAbs for SARS-CoV-2. VNARs are the smallest (~11 kDa)
naturally occurring independent heavy chain-only binding
domains in the vertebrate kingdom. Part of the adaptive
immune system of sharks, VNARs are evolutionarily distinct
from immunoglobulins despite sharing some structural simi-
larity with mammalian heavy and light variable chains. VNARs
further differentiate themselves from classical antibodies and
single-domain camelid antibodies by lacking a CDR2, but
possess the benefits of two additional hypervariable loops (HV2
and HV4), yielding a total of four loops of diversity into their
small and simple domain architecture8. With characteristic
protruding paratopes, the VNARs are pre-disposed to access
and bind epitopes not normally available to the planar binding
sites of classical human antibodies. This feature allows for the
identification of highly potent binders that reach deep into
pockets and grooves within the target antigen9–11. Furthermore,
their amenability to reformatting, cost-effective expression at
scale in non-mammalian systems, and exceptional stability in
diverse formulation conditions, makes VNARs ideal for clinical
translation12,13.
Here, we describe the identification and characterization of three
monomeric antiviral VNARs (3B4, 2C02, 4C10) that were found to
be potent neutralizers of pseudotype and authentic SARS-CoV-2
virus. These VNARs were uniquely potent as monovalent con-
structs, with efficacies rivalling multimeric variable-heavy-heavy
(VHH) camelid antibodies and Fc-bound bivalent constructs,
including conventional full-length immunoglobulins. The crystal
structures of VNARs 3B4 and 2C02 showed markedly different
mechanisms of neutralization and underscored the likely resilience
of VNARs to SARS-CoV-2 variants. Additionally, the VNARs
showed neutralization capabilities against other beta coronaviruses
supporting the potential broad therapeutic application of these
VNARs and the VNAR platform against both known diseases and
future emergent disease. Together the three VNARs described here
reinforce the need for the continued expansion of the single-
domain heavy-chain only antibody-like drug class.
RESULTS
Identification of VNARs against SARS-CoV-2. After four
rounds of biopanning against the SARS-CoV-2 RBD with the
ELSS libraries each containing ~10 billion clones, we isolated
nearly two dozen unique VNAR domains that bound to the RBD
by ELISA (Fig. 1a). As a primary method for identifying potent
inhibitors of viral entry, we screened VNARs in a luciferase-based
infectivity assay. Increasing concentrations of VNARs were used
to neutralize pseudotyped SARS-CoV-2 and SARS-CoV-1 in
ACE2-expressing HEK293T cells using luciferase activity as a
readout for viral infectivity (Fig. 1b). As a positive control for our
primary screen, we used VHH-72-Fc, a previously identified
bivalent single-domain camelid antibody14. In our hands, VHH-
72-Fc potently neutralized both SARS-CoV-2 and SARS-CoV-1
(IC50= 1.49 nM± 0.25 nM and IC50= 20.2 nM± 2.7 nM, respec-
tively), values consistent with the literature. From this screen,
VNARs with IC50 values below 10 nM were prioritized for further
characterization (Fig. 1c). This resulted in the identification of
three lead VNARs: 3B4, 2C02, and 4C10. For subsequent controls,
we selected a VNAR with relatively low neutralization potency
(2D01) and a non-targeting naïve VNAR (2V).
Virus neutralization experiments were next conducted against
a series of pseudotyped viruses (Fig. 1D). These secondary
validation experiments were performed in Calu-3 cells, an ACE2-
expressing human bronchial epithelia cell line that is susceptible
to infection by beta-coronaviruses15. Our four VNARs were
tested for concentration-dependent neutralization of pseudotyped
SARS-CoV-2 and SARS-CoV-1 in this cell line. We also screened
for cross-reactivity with the pre-emergent ‘SARS-like’ corona-
virus, WIV1-CoV, which currently circulates throughout bat
populations and displays human tropism via hACE216. Addi-
tionally, we assessed neutralization of pseudotyped Middle East
respiratory syndrome coronavirus (MERS-CoV), a phylogeneti-
cally distant beta-coronavirus which utilizes human DPP4 as a
host-cell receptor17,18. As a negative control, we screened our
panel of VNARs for neutralization of viral particles pseudotyped
with vesicular stomatitis virus glycoprotein (VSV-G), an
unrelated enveloped virus.
The neutralization potency of the VNARs (3B4, 2C02, 4C10)
against pseudotyped SARS-CoV-2 and SARS-CoV-1 was faith-
fully reproduced in Calu-3 cells and HEK293T-hACE2 cells
(Fig. 1d–f, Supplementary Fig. 1 Supplementary Table 1). As
expected, VNAR-2D01 displayed ~10-fold lower potency
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-27611-y
2 NATURE COMMUNICATIONS |         (2021) 12:7325 | https://doi.org/10.1038/s41467-021-27611-y | www.nature.com/naturecommunications
compared to 3B4, 2C02 or 4C10 (Fig. 1d, Supplementary Table 1).
High concentrations of non-targeted VNAR-2V had no effect on
viral infectivity (Fig. 1f). Each VNAR effectively neutralized viral
infectivity of pseudotyped WIV1-CoV suggesting that each
VNAR likely binds to epitopes conserved among ‘lineage B’
beta-coronaviruses17. In contrast, VNAR-3B4 was uniquely
effective at neutralizing cellular entry of viral particles
pseudotyped with MERS-CoV spike proteins, a ‘lineage C’ beta-
coronavirus, despite sharing only 32% sequence homology with
SARS-CoV-2 Spike (Fig. 1d–f)17. This observation suggests that
VNAR-3B4 likely binds to an interface that is evolutionarily
conserved among beta-coronavirus lineages. Importantly, the
inhibitory activity observed by these VNAR antibodies was
specific to coronaviruses and was not due to deleterious effects on
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cell health, as demonstrated by the lack of effect on either
pseudotyped VSV infectivity or cell viability (Fig. 1e, f).
Finally, we tested the neutralizing efficacy of the VNARs against
replication-competent SARS-CoV-2 (strain USA_WA1/2020) in
Vero E6 cells (Fig. 1g). In this system, VNAR-3B4 displayed a
modest loss of potency (IC50= 11.5 nM± 5.4 nM), while VNARs-
2C02 and 4C10 were both found to be ~10-fold more potent
compared to data collected from pseudovirus experiments (IC50=
0.84 nM± 0.15 nM, and IC50= 0.61 nM± 0.26 nM, respectively).
As expected, 2D01 was the least potent anti-SARS-CoV-2 RBD
VNAR antibody (IC50= 4.6 μM± 1.2 μM), and VNAR-2V failed to
have any impact on viral infectivity. IC50 values for neutralization
of replication-competent SARS-CoV-2 are collated in Table 1.
Altogether, these data demonstrate that VNARs 3B4, 2C02, and
4C10 are potent and effective monomeric anti-viral VNARs.
Structural basis for SARS-CoV-2 neutralization by VNARs. To
understand the mechanism of neutralization, we determined the
crystal structure of SARS-CoV-2 spike RBD in complex with
VNARs 3B4 and 2C02 at 1.92-Å and 1.96-Å resolution, respec-
tively. The structures show that VNARs 3B4 and 2C02 recognize
distinct epitopes on the RBD surface (Fig. 2a, Supplementary
Fig. 2), neither of which overlaps with the ACE2 receptor inter-
face. VNAR-3B4 binds distal to the ACE2 binding interface with
no direct interaction with the residues involved in ACE2 recog-
nition. This epitope is only accessible to 3B4 when the RBD is in
the “up” conformation and is blocked by the N-terminal domains
(NTD) of other spike protomers when the RBD is in the “down”
position (Fig. 2b, upper inset). Alignment of the 3B4 crystal
structure with an available cryo-EM structure of the full spike
protein bound to the host receptor ACE2 shows that the frame-
work of 3B4 likely clashes with ACE2 when the RBD is in the
“up” conformation. This suggests that the mode of neutralization
for 3B4 is through steric occlusion rather than direct competition
with the ACE2 binding site (Fig. 3a). This mechanism is similar to
Class 1 NAbs as characterized by Barnes, et al, which bind only to
“up” RBDs and also block ACE2 binding in some form19.
The structure of the RBD in complex with VNAR-2C02
revealed that it binds to the opposite side of the RBD than
VNAR-3B4. This epitope is accessible to VNAR-2C02 when the
RBD is in the “up’ or “down” conformation (Fig. 2c, lower inset).
In contrast to VNAR-3B4, superposition of the VNAR-2C02
crystal structure with the cryo-EM structure of the spike trimer in
complex with ACE2 shows that VNAR-2C02 does not come into
close contact with ACE2, suggesting that neutralization is not a
result of a steric clash with ACE2, but rather through allosteric
effects that decrease the population of “up” RBDs that are
available to bind ACE2 for viral entry (Fig. 3b). This mechanism
is in line with Class 3 NAbs that bind outside of the ACE2
interface19. Interestingly, alignment of the VNAR-2C02 structure
to an RBD in the “down” conformation in the full-trimer reveals
that it binds in a cleft that is formed between the RBD from
protomer 1 and the NTD of protomer 3 (Fig. 3c). It is possible
that the enhanced efficacy of VNAR-2C02 observed in the viral
neutralization assays is a result of additional interactions between
VNAR-2C02 and the NTD in this cleft. In this mode, VNAR-
2C02 would act to pin the “down” RBD and NTD together and
prevent the RBD from sampling the “up” conformation that is
necessary for attachment to ACE2, though this remains to be
confirmed structurally. This indirect mechanism for blocking
ACE2 binding would pair well with other NAbs that directly
block ACE2, such as 3B4. The combined neutralization mechan-
isms of 3B4 and 2C02 would therefore be most therapeutically
beneficial when co-administered.
The small binding profile of this class of antibody allows
VNARs to pack tightly against the RBD and access binding motifs
not accessible to conventional antibodies. The primary interac-
tion interface of VNARs 3B4 and 2C02 covers 734 Å2 and 792 Å2,
respectively. Each VNAR covers less area than a standard bivalent
antibody, yet still maintains exquisite target specificity. For
VNAR-3B4, its interaction was dependent on only 5 residues in
the CDR3 region of the VNAR and 7 total residues in the spike
RBD. Residues Glu122, His124, Asp126 of CDR3 form an anti-
parallel β-sheet with residues Ser375, Phe377, and Cys379 in the
β2-strand of the RBD (Fig. 4a). The extensive hydrogen bond (h-
bond) pairing of these backbone residues likely accounts for
much of the affinity of the interaction, and because it is not
dependent on sidechain participation, it makes this part of the
interaction primarily residue independent. All three residues of
3B4 that form direct β-sheet interactions, Glu122, His124, and
Asp126, also participate in some form of sidechain h-bonding. In
addition to the backbone-backbone interactions above, there is
also an elaborate h-bond network formed between the terminal
amines of Arg103 of 3B4 with the backbone carbonyls of Ala372
Fig. 1 Shark VNARs potently and effectively neutralize the infectivity of multiple coronaviruses. a ELISA screen for identification of potential SARS-CoV-
2 RBD binders. Negative control wells containing expression media, and positive control wells containing VNAR E06 (anti-serum albumin) and rabbit
monoclonal CR3022-RB (anti-SARS-CoV-2 Spike) are indicated. b Primary screen for identification of neutralizing VNAR domains. Concentration-
dependent neutralization of pseudotyped SARS-CoV-2 (black) or SARS-CoV-1 (red) in HEK293T cells transiently expressing ACE2. Data represents
mean ± s.e.m. relative luminescence units (RLUs) from n= 3 independent biological experiments. c Left, rank-ordered IC50 values for neutralizing VNARs
from panel (b). VNARs with IC50 < 10 nM (dashed line) were selected for further characterization. Upper right, depiction of primary sequences of selected
VNARs, relative length of complementarity determining regions (CDR1, CDR3) and location of cysteine residues (teal) are shown. d Phylogenetic tree of
selected virus taxa, divergent lineages of betacoronaviruses are shown. Glycoproteins encoded by the indicated viruses (*) were used to generate
pseudoviruses. e Heatmap summarizing IC50 values for neutralization of the indicated pseudovirus with the indicated VNAR antibody. Values are derived
from experiments described in (f). f Secondary validation of selected neutralizing VNAR domains. Concentration-dependent neutralization of viral particles
pseudotyped with glycoproteins natively encoded by either SARS-CoV-2 (black), SARS-CoV-1 (red), WIV1-CoV (blue). MERS-CoV (green), or VSV
(purple) in Calu-3 cells. Cell viability was also assessed in the presence of increasing concentrations of VNARs (yellow). Data represents mean ± s.e.m.
RLU values from n= 3 independent biological experiments. g Concentration-dependent neutralization of replication-competent authentic SARS-CoV-2,
strain USA_WA1/2020 in Vero E6 cells. Data represents mean ± s.e.m. RFU values from n= 3 independent biological experiments.
Table 1 VNAR IC50 values for neutralization of SARS-CoV-2.
VNAR SARS-CoV-2 USA_WA1/2020
3B4 1.15E-8 ± 5.4E–9
2C02 8.39E-10 ± 1.5E–10
4C10 6.13E-10 ± 2.56E–10
2D01 4.60E-6 ± 1.2E–6
2V NA
Half maximal inhibitory concentrations for neutralization of replication-competent SARS-CoV-2
(strain USA_WA1/2020) in Vero E6 cells. Values were calculated from data representing three
independent biological experiments. NA, calculated IC50 not available.
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and Phe374 that is supported by a side-on intramolecular
interaction between Asp126 and Arg103 of 3B4 (Fig. 4b). Another
sidechain-backbone interaction occurs between His124 of VNAR-
3B4 and the backbone carbonyl of RBD Tyr369. Two sidechain-
sidechain h-bonds complete the extent of the interaction – one
between Asp107 of 3B4 and Tyr369 of the RBD and a second
between Glu122 of VNAR-3B4 and Ser383 of the RBD (Fig. 4b).
The interaction of VNAR-2C02 is dependent on 9 residues
separated between the HV2 and CDR3 regions of the VNAR and
12 total residues in the spike RBD. While the 3B4 interaction
depended primarily on h-bonding, the interaction of 2C02 largely
relies on hydrophobic interactions. Hydrophobic residues Ala348,
Ala352, Leu452, Ile468, Phe490, and Leu492, along with the
aromatic residue Tyr351, create a nonpolar patch on the RBD
which then interfaces with Tyr54, Leu105, and Phe116 of VNAR-
2C02 (Fig. 4c). Though Thr53 of VNAR-2C02 is considered
polar, the nonpolar methyl group of its side chain appears to be
taking part in the hydrophobic core of this interaction. A number
of h-bonds help to stabilize the binding of VNAR-2C02 to the
RBD (Fig. 4d). RBD residues Asn354 and Arg466 form an h-bond
network with Asn115 of 2C02, though the electron density of the
crystal structure indicates that multiple rotameric states of
Arg466 are possible. Multiple rotamers were also revealed in
the density for Arg346 on the RBD indicating that Arg346
transiently h-bonds with Tyr118 or the backbone carbonyl of
His117 in VNAR-2C02 (Fig. 4d, oval inset). Arg67 of VNAR-
2C02 takes part in two interactions: first, it forms a salt bridge





















Fig. 3 Structural analysis of VNAR 3B4 and 2C02 suggests two unique mechanisms of neutralization. a Inset shows the crystal structure of the spike
trimer with the RBD in the “up” orientation (green) bound to ACE2 (purple) (PDB ID: 7DF4). An alignment of the RBD (white) from the ACE2 (purple) and
the VNAR-3B4 (blue) crystal structures. b Inset shows the crystal structure of the spike trimer with the RBD in the “up” orientation bound to ACE2 (purple)
(PDB ID: 7BF4). An alignment of the RBDs (white) from the ACE2 (purple) and the VNAR-2C02 (yellow) crystal structures. c Figure inset shows the
orientation of the main panel with a top-surface view of the spike trimer with numbered protomers and all RBDs in the “down” position (aligned from PDB:





























Fig. 2 VNARs 3B4 and 2C02 bind to distinct epitopes on the SARS-CoV-2 RBD. a Transposed structures of VNAR 3B4 (blue) and 2C02 (yellow)
complexes aligned to the RBD colored white as a surface representation. b SARS-CoV-2 RBD shown as a surface representation in gray with the ACE2
binding interface colored purple. A cartoon representation of VNAR-3B4 depicted in blue bound to the RBD. Inset shows a surface view of the top of the
full-spike trimer with the RBD colored red in the “RBD-down” conformation and colored green in the “RBD-up” conformation with VNAR-3B4 in blue. c A
180-degree rotation of the SARS-CoV-2 RBD is shown as in Panel A with a cartoon representation of VNAR-2C02 (yellow) bound to the RBD. Inset shows
a surface view of the top of the full-spike trimer with the RBD colored as in Panel A with two VNARs colored in yellow.
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with RBD Phe490. Lastly, Ser63 forms a backbone h-bond with
the carbonyl of RBD Gly446.
VNARs cross-react with closely related coronaviruses. In order
to understand how our VNARs might bind to the RBD of related
coronaviruses, we performed sequence alignments of the three
coronaviruses and homology modeling of VNAR-3B4 bound to
SARS-CoV-1 and MERS, and VNAR 2C02 bound to SARS-CoV-
1. Alignment of the SARS-CoV-1 and SARS-CoV-2 sequences
show that there is a high degree of sequence homology between
the RBDs, with almost complete conservation in the VNAR-3B4
epitope (Fig. 5a, blue box). A surface view of the RBD shows that
most of the sequence variation occurs primarily at the ACE2
binding interface while the VNAR-3B4 interface remains similar
(Fig. 5b, top). Among the critical interacting residues, there is a
threonine in SARS-CoV-1 in place of the alanine in SARS-CoV-2
of which the backbone carbonyl, and not the sidechain, is the key
interactor. Homology modeling of the complex between VNAR-
3B4 and the SARS-CoV-1 RBD shows that the critical interac-
tions, including the alanine to threonine change, are likely similar
in the SARS-CoV-1:VNAR-3B4 complex (Fig. 5c, top). Crucially,
the anti-parallel β-sheet between CDR3 of 3B4 and β2-strand of
the RBD as well as the arginine h-bond network are also a key
part of the interaction in the model. Alignment of the modeled
SARS-CoV-1 RBD with a crystal structure of the SARS-CoV-1
RBD bound to ACE2 (PDB id: 2AJF) shows that the modeling
imposed very little structural distortion to align the residues,
indicating that only a modest rearrangement of the RBD frame-
work is needed to accommodate binding of 3B4 (Fig. 5d, top).
In contrast to the conservation of the VNAR-3B4 epitope, the
VNAR-2C02 epitope is less conserved. Among the 12 interact-
ing residues in SARS-CoV-2, only 5 interactions are conserved
in SARS-CoV-1 (Supplementary Fig. 3A, B). Interestingly,
homology modeling of the SARS-CoV-1 RBD:VNAR-2C02
complex indicated that similar or replacement interactions take
place and that the bulk of the hydrophobic core interactions
were intact. Among the 7 residues that are part of this key
hydrophobic interaction, four were conserved, two were
replaced by residues with similar properties, and only one
(L452) is lost (Supplementary Fig. 3A, see arrow annotations).



















































Fig. 4 VNARs 3B4 and 2C02 bind the SARS-CoV-2 RBD through uniquely different interactions. a Stick representation of the peptide backbone in the
primary interaction interface. Interactions between residues Ser-375, Phe-377 and Cys-379 of the RBD (white) and Glu-122, His-124, and Asp-126 of 3B4
(blue) are shown as black dashes. Inset shows the orientation of the zoomed in view. b A 180-degree view of the interaction interface. Interactions between
residues of the RBD (white) and 3B4 (blue) are shown as yellow dashes with black dashes. Inset shows the orientation of the zoomed in view.
c Transparent spheres surrounding the stick representations of residues involved in the hydrophobic interactions between the RBD (white) and VNAR-
2C02 (yellow). Inset shows the orientation of the zoomed in view. d A 180-degree view of the interaction interface between the RBD (white) and 2C02
(yellow). Residues are shown as sticks with yellow dashes representing hydrogen bonds between atoms. Rounded insets show an alternate view of
interactions that are partially obscured from view in the main panel. Top inset shows the orientation of the zoomed in view.
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non-polar like residue when cyclic, and the aromatic residue
Phe490 has been replaced by Trp476 (Supplementary Fig. 3C).
Conserved residues Tyr338 and Arg453 can still h-bond with
His117 and Asn115 of 2C02, respectively. Fortunately, most
residues that changed are still able to form similar h-bonds.
Among these changes, a variation of Asn354 to Glu341 can still
accept an h-bond from the backbone amine but it can no longer
donate an h-bond to the carbonyl of the Asn115 of VNAR-
2C02. The final major difference between the SARS-CoV-2
structure and the SARS-CoV-1 model is a result of the deletion
of a residue equivalent to Glu484. This change results in the
loss of an important salt bridge that forms with Arg67 of
VNAR-2C02. However, the change of a similar aromatic
residue, Phe490 to Trp476, allows Arg67 of VNAR-2C02 to
maintain its cation-pi interaction.
Greater variation exists between the SARS-CoV-2 and the
MERS RBDs, with only 3 of the 7 interacting residues in the
VNAR-3B4 epitope remaining (Fig. 5a, blue box). A surface view
of the MERS RBD shows that the sequence variation occurs
throughout the RBD (Fig. 5b, bottom). The MERS RBD binds
DPP4 instead of ACE2 and a large degree of structural and
sequence variation would be expected. Homology modeling
of VNAR-3B4:MERS RBD complex found that many of the
backbone interactions, including those of the antiparallel β-sheet
and arginine h-bond network could still interact (Fig. 5c, bottom).
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KLRPFER - D I SNVPFSPDGKPCTPP - ALNCYWPLNDY - - - GFYTTTG IYNYKLPDDFMGCVLAWNTRN I DATSTGNYNYKYRYLRHG
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Fig. 5 The VNAR-3B4 epitope is highly conserved between closely-related coronaviruses. a Sequence alignment between SARS-CoV-1, SARS-CoV-2,
and the MERS RBDs. Residues different from SARS-CoV-2 are highlighted in red and the interaction interface for VNAR-3B4 is marked with a blue box.
Bolded letters indicate residues critical for the interaction between the RBD and 3B4 with arrows indicating the residues that form a backbone beta-sheet.
The sequence alignment is numbered above according to SARS-CoV-2. b Surface representations of SARS-CoV-1 (pink, above) and MERS (green, below)
with variant residues colored red. The ACE2 binding interface is highlighted in purple for SARS-CoV-1 and the DPP4 binding interface in orange for MERS.
The homology-modeled interaction interface for 3B4 is colored blue for both structures. c Zoomed in view of the modeled interaction interface between
3B4 (blue) and SARS-CoV-1 (pink, above) and MERS (green, below), with 3B4 colored blue in both pictures. Interacting residues are highlighted as in Fig. 2,
showing the backbone interactions in black dashes and sidechain to backbone or sidechain to sidechain interactions shown as yellow dashes. Insets show
the orientation of the zoomed in view. d Overlays of the 3B4 interface from modeled RBDs and their matching RBDs obtained by x-ray crystallography. The
panel above shows the modeled SARS-CoV-1 RBD, colored pink, aligned with the crystal structure of SARS-CoV-1 RBD bound to ACE2 (PDB id: 2AJF),
colored magenta. The panel below shows the modeled MERS RBD, colored light green, aligned with the crystal structure of MERS RBD bound to DPP4
(PDB id: 4L72), colored dark green.
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of 3B4 remained, the change from a tyrosine to a leucine certainly
eliminates one h-bond formed with Asp107 of VNAR-3B4. It was
much less likely that all these interactions remain the same when
comparing the modeled MERS RBD to the crystal structure of the
MERS RBD bound to its receptor DPP4 (PDB id: 4L72). This
alignment has an RMSD of 4.137, indicating that the model and
x-ray structure are very dissimilar and that a large structural
rearrangement of the MERS RBD framework is needed to fully
accommodate the binding of 3B4 (Fig. 5d, bottom). Visual
inspection of the alignment shows that the modeling constraints
forced both the α1 and α2 helices that surround the β2-strand of
the interaction to unwind a single helical turn in order to allow
the β2-strand flexibility to interact with 3B4. Such a large
structural rearrangement would not be favorable, and it is
unlikely that the homology modeling accurately represents the
interaction between the MERS RBD and VNAR-3B4. Realisti-
cally, the conserved Phe, Cys, and Ser residues of the VNAR-3B4
epitope are the only likely interactions, and the remaining β-sheet
and arginine network hydrogen-bonding are lost. Deletion of the
h-bonding that occurs between the VNAR and the RBD would
explain why VNAR-3B4 weakly binds the MERS RBD and is
moderately effective at neutralization of pseudovirus.
VNARs bind SARS-CoV-2 variants. Emerging mutant strains of
SARS-CoV-2 remain a threat to the control of the pandemic.
Viral variants are more easily transmissible, and it is uncertain if
current vaccine formulations will remain efficacious against them.
The CDC is currently monitoring several variants of concern
(VOC), including the prominent Alpha and Beta variants that
first emerged in the UK and South Africa, respectively, as well as
the more recent Delta variant that first appeared in India (Fig. 6).
The spike protein is highly susceptible to mutation and many
prominent mutations that occur within the RBD alter the inter-
action with the host ACE2 by enhancing the binding properties
(affinity) of the spike protein to ACE2. It is also likely that
mutations which affect the ACE2/RBD interface would also
diminish or prevent binding of neutralizing antibodies that
directly compete at this site.
To visualize the potential influence of RBD mutations on the
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Fig. 6 VNAR binding is resistant to emerging RBD mutations. For panels (a) and (b), all reported mutation sites (as curated by CDC.gov) are colored
green in each RBD structure and the ACE2 binding interface is annotated in purple. The list of mutation sites is shown in the center of the figure with
arrows drawn to indicate the mutation sites that appear in each of the primary variants of concern (V.O.C). a Surface representation of the RBD with
the 3B4 binding interface colored in blue. Insets show mutation sites that occur proximal to 3B4, top: (R408) and bottom:(W436, N439, N440, N501).
b A 180-degree rotation of the RBD with the 2C02 binding interface colored in yellow. Inset shows mutations that are a part of or proximal to the 2C02
interface (L452, E484, F490). c A cartoon representation of the RBD with an outline of the surface with mutation sites K417, E484, and N501 displayed as
orange sticks. d Summary of binding affinities (KD) for each of the VNARs to the WT SARS-CoV-2 RBD in comparison to the triple mutant RBD indicated in
(c). Data shown are a result of triplicate experiments using a BLI binding schema with biotin labeled RBDs (see methods).
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growing list curated by the CDC to the RBD of the VNAR-3B4
and 2C02 crystal structures (Fig. 6). Mutation mapping revealed
that most of the RBD mutations occur distal to the VNAR-3B4
epitope and are primarily located in the ACE2 binding interface
(Fig. 6a). The most proximal mutation sites to VNAR-3B4 (R408,
W436, N439, N440, and N501) do not interact with the VNAR,
and there are no apparent amino acid changes that would create a
clash with VNAR-3B4 at these sites (Fig. 6a, top and bottom
insets). This analysis suggests that VNAR-3B4 will not lose its
ability to neutralize current SARS-CoV-2 viral variants. Several
mutation sites, however, occur directly in the interface of 2C02.
Sites L452, E484, and F490 play a direct role in the binding of
2C02, suggesting that 2C02 binding would be altered when
binding to viral variants that include these mutation sites
(Fig. 6b).
To assess the ability of our VNARs to neutralize variants, we
performed biolayer interferometry (BLI) to compare VNAR
binding to both WT and mutants RBD (Supplementary Fig. 4). A
mutant RBD from the Beta variant, which also contained
mutations found in other VOCs, was used (Fig. 6c). Results
from the BLI experiments confirmed our initial prediction that
these mutations have little to no effect on the affinity of 3B4
(Fig. 6d). Surprisingly, the loss of the salt bridge interaction
between VNAR-2C02 and E484 did not have a strong effect on
the affinity of VNAR-2C02 (Fig. 6d), further indicating that the
VNAR-2C02 interaction is predominantly the result of hydro-
phobic interactions. While we do not have any structural data for
the binding location of VNAR-4C10 on the RBD, the BLI
experiments showed that these mutations do not have a
substantial effect on VNAR-4C10 affinity as well. Taken together,
the mutational mapping analysis and BLI data strongly indicate
that the use of VNARs will remain useful neutralizing agents to
combat variant strains of the SARS-CoV-2 virus.
Discussion
Successfully combating the COVID-19 pandemic will require the
use of multiple therapeutic modalities rather than reliance on a
singular therapeutic tool. Though vaccines will be responsible for
controlling disease spread in a majority of cases, vaccines are not
a panacea. Research has documented that a subset of individuals
is not protected from SARS-CoV-2 infection even after receiving
the two dose vaccination regimen and vaccines are not a viable
option for immune-compromised individuals5,20. In this study,
we detail the development of a class of single-domain VNAR
binders as neutralizing agents against SARS-CoV-2. Identified by
phage display using high-diversity libraries, our lead monomeric
VNARs (3B4, 2C02, and 4C10) were able to potently neutralize
pseudotype and authentic live SARS-CoV-2 virus at nano and
picomolar concentrations. In addition to SARS-CoV-2, the
VNARs were able to neutralize closely related coronaviruses,
including SARS-CoV-1, and pre-emergent zoonotic viruses
(WIV1). One binding domain, VNAR-3B4, was capable of neu-
tralizing coronaviruses across multiple phylogenetic lineages
(class 2B and class 2C), owing to partial sequence conservation of
the 3B4 epitope. The small size and protruding CDR3 makes 3B4
uniquely effective at accessing this conserved epitope, under-
scoring the utility of neutralizing VNAR domains. Our data also
suggest that the three VNARs we identified would be effective at
neutralizing the existing Alpha, Beta, and Delta variants as well as
variants yet to emerge. Should vaccination fail due to the emer-
gence of a viral variant, alternative therapies like our VNARS,
alone or in combination, are essential to maintaining control over
the spread of the virus.
At a molecular weight of approximately 11 kDa, VNARs are
smaller than the fragment of antigen-binding domains of human
and mouse antibodies (~50 kDa) and even single-domain camelid
VHH antibodies (~15KDa). After the initial pseudovirus screen to
identify potent neutralizers from our libraries, none of the can-
didate VNARs underwent affinity maturation and were subse-
quently characterized as purely monomers. In pseudotype and
authentic virus assays, our three lead VNARs performed as well
or better than other neutralizing antibodies reported in the
literature21. Of significance, two VNARs (2C02 and 4C10) had
picomolar neutralization IC50 values in the authentic virus assay
(840 pM and 613 pM respectively). Our VNARs were more
effective at neutralization compared to other monovalent single-
domain antibodies derived from camelids. In a previous study,
investigators found that tethering the affinity matured camelid
antibody mNb6 in triplicate to form a trimer (mNb-tri) resulted
in a highly potent construct with low picomolar neutralization
IC50 values against both pseudo and authentic SARS-CoV-2 virus.
Remarkably, the IC50 values of this trivalent construct were only
one order of magnitude lower than our monovalent VNAR-4C10.
As a positive control in our initial VNAR screen we used VHH-
72-Fc, a bivalent form of the camelid VHH-72. Though not
effective at neutralizing pseudovirus as monomer, VHH-72-Fc
had a low nanomolar potency (1.5 nM) which was only slightly
better than our best VNAR (2C02 - 2.8 nM). These findings
highlight the ability and versatility of the diminutive VNAR
scaffold for the development of highly specific and effective
agents against a given target.
Not only do VNARs 3B4 and 2C02 bind the SARS-CoV-2 RBD
at different epitopes, but their primary modes of interaction were
also completely different. Analysis of the crystal structures
revealed that VNAR-3B4 relied heavily on hydrogen bonding
while hydrophobicity was at the core of VNAR-2C02 binding to
the RBD. Interestingly, only two of the interactions in VNAR-3B4
were dependent on RBD residue identity, as the majority of
hydrogen bonding occurred in direct contact with the peptide
backbone of the spike RBD. We also found that VNAR-3B4
bound the RBD solely via its CDR3, the canonical VNAR para-
tope. In the case of VNAR-2C02, 7 of the 12 interface residues of
the RBD have hydrophobic qualities driving the interaction. This
feature also makes the 2C02 interaction residue independent to
the extent that residue identity of this interface maintains its non-
polar features. In addition to binding through the CDRs, the
interaction between VNAR-2C02 and RBD was supported by two
residues in the HV2 region, Ser63 and Arg67, providing addi-
tional evidence for the functional significance of the HV2
domain. The partial residue independence of each interaction
indicates that VNARs 3B4 or 2C02 as a treatment could maintain
potency for binding the RBD in emerging spike mutants or other
coronaviruses. This independence is further illustrated by the BLI
experiment with VNAR-2C02 and the Beta variant RBD.
Although Arg67 of VNAR-2C02 forms a salt bridge with E484 of
the wild type RBD, loss of that salt bridge in the variant RBD did
not have a significant effect on VNAR binding.
Comparison of the VNARs to other NAbs in the literature
reveals distinct differences about their epitopes and mechanisms
of action. VNAR-3B4 binds an epitope on the RBD that is highly
conserved between SARS-CoV-1 and SARS-CoV-2 that is distal
to the ACE2 binding interface. The VNAR-3B4 epitope partially
overlaps with other NAbs reported in the literature including the
human IgGs CR3022 and EY6A (Supplementary Fig. 5A)22–24.
While CR3022 and EY6A destabilize spike protein by trapping
the RBD in the “up” conformation, they do not result in a direct
steric clash with ACE2 like VNAR-3B4. VHH-72 binds near the
VNAR epitope and makes similar backbone interactions to
VNAR-3B4 (Supplementary Fig. 5B)14. VNAR-3B4 and VHH-72
bind to the RBD on opposite sides of the conserved fold resulting
in binding modes that are quite distinct. VNAR-2C02 likely
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neutralizes by pinning the RBD in the down position, thus
blocking access to ACE-2. Antibodies Fab 2–4 and BD23 neu-
tralize through a similar mechanism, however, there is minimal
epitope overlap with VNAR-2C02 (Supplementary Fig. 6A)19,25.
There is epitope overlap between VNAR-2C02 and Nanosota-1, a
neutralizing VHH that was recently identified from our nanobody
library. VNAR-2C02 and Nanosota-1 can both bind the RBD in
down conformation, but Nanosota-1 directly blocks ACE2
binding and also recognizes a number of mutational prone resi-
dues in the ACE2 binding interface (Supplementary Fig. 6A)26.
There is partial epitope overlap of VNAR-2C02 with other NAbs,
however, those antibodies act through ACE2 antagonism rather
than through a potential bivalent RBD-NTD interaction that pins
down the RBD7. Importantly, the separate epitopes of 3B4 and
2C02 suggest that they would be therapeutically effective as a
multi-NAb cocktail, similar to the REGEN-COV antibody cock-
tail of casirivimab and imdevimab, which bind to closely located
epitopes. Taken together, our VNARs occupy a unique molecular
space that have potential to completely alter the landscape of
biologics by making antibody-class drugs even smaller, yet as
potent and efficacious.
Methods
Plasmids. Plasmids used for generating pseudovirus stocks were sourced as fol-
lows: plasmid encoding an Env-defective, luciferase-expressing HIV-1 genome
(pNL4-3.luc.R-E−)27,28 was obtained through the NIH AIDS Reagent Program;
plasmids encoding SARS-CoV-1 and SARS-CoV-2 Spike were from Fang Li
(Addgene plasmid #145031 and #145032, respectively)29; WIV1-CoV Spike was
from Alejandro Balazs (Addgene plasmid #164439)30; MERS-CoV Spike was from
Sino Biological (VG40069-NF); and VSV-G was from Bob Weinberg (Addgene
plasmid #8454).
Cell culture. HEK293T cells (human embryonic kidney), Vero E6 cells and Calu-3
cells were purchased from ATCC. HEK293T cells stably overexpressing human
angiotensin-converting enzyme 2 (HEK293T-hACE2) were sourced from BEI
Resources (NR-52511). All cells were maintained in DMEM supplemented with
10% fetal bovine serum, 100 units/ml penicillin and streptomycin, 292 µg/ml L-
glutamine and cultured at 5% CO2 and 37 °C. All cell culture reagents were pur-
chased from Thermo Fisher.
Recombinant SARS-CoV-2 RBD. Recombinant RBD expressed in Chinese ham-
ster ovary cells was generous gift from Fang Li, PhD (University of Minnesota,
Department of Veterinary and Biomedical Sciences) and was also purchased from
R&D Systems (cat #10534-CV). Prior to biotinylation, ~0.5 mg of the RBD in
20 mM Tris-HCl, 200 mM NaCl was dialyzed against phosphate-buffered saline
(PBS, pH 7.4) for 4 h using Slide-A-Lyzer™ cassettes, 10 K MWCO (Thermo Sci-
entific) to remove tris-base. Biotinylation (1–3 biotins per RBD molecule) was
achieved using EZ-Link Sulfo-NHS-LC-Biotinylation Kit (Thermo Scientific) fol-
lowing manufacturer’s instructions, and a final dialysis against PBS, pH 7.4 to
remove excess biotin. All phage display selection rounds were conducted with
biotin-RBD, while screening (including binding ELISA) was conducted with non-
biotinylated RBD protein. For the crystal structure in complex with VNAR 2C02,
RBD expressed in insect cells was used.
Identification of SARS-CoV-2 VNARs. Elasmogen’s proprietary next-generation
synthetic, multi-framework VNAR libraries (ELSS) were constructed by combining
naïve VNAR frameworks, varying CDR3 lengths, inclusion of sequence diversity
within CDR1 and CDR3, and in some cases, incorporation of non-canonical
cysteine residues in CDR1 and CDR3. These closely related libraries represent
either type II or IIb (also referred to as type IV) VNARs9,10. VNAR binders to the
SARS-CoV-2 RBD were isolated from these ELSS libraries. The libraries were
maintained in Elasmogen’s proprietary phagemid vector with a diversity of
~2 × 1010 unique clones. Each library was inoculated into 2X TY growth media
supplemented with 1% glucose (w/v), 100 µg/mL ampicillin (2X TY-Amp/Glu) and
grown at 37 °C to mid-log phase (OD600 of 0.45–0.6) prior to infection with
M13K07 helper phage for 30 min in a static 37 °C incubator to obtain a phage
rescued library of VNAR-presenting phage. This infected culture was re-suspended
in fresh 2X TY media supplemented with 100 µg/mL ampicillin, 50 µg/mL kana-
mycin (2X TY-Amp/Kan) and incubated overnight at 30 °C on a shaking platform.
Phage was PEG-precipitated from the culture supernatant and used for round one
of bio-panning. The phage VNAR library, was panned against biotin-RBD cap-
tured on Dynabeads™M-280 Streptavidin (Thermo Fisher Scientific). Library phage
and Dynabeads™ were pre-blocked (3% (w/v) milk in PBS - MPBS) for 1 h, at room
temperature on a disc rotator. Biotin-RBD (400 nM) was added to blocked
Dynabeads™, incubated for 1 h, rotating at room temperature. Non-specific phage
were deselected from the library by incubating with blocked beads for 1 h at room
temperature. Biotin-RBD (~400 nM) decorated Dynabeads™ were incubated with
deselected phage for 1 h, rotating at room temperature (round 1). Beads were
washed 5X with PBST and PBS before eluting with 100 mM triethylamine and
neutralized by adding 1 M Tris-HCl pH 7.5. Mid-log phase E. coli TG1 cells were
infected with eluted phage for 30 min, at 37 °C, and plated on 2X TY agar plates
supplemented with 1% glucose and 100 µg/mL ampicillin. Three additional rounds
of selection were conducted using the same antigen concentration, and wash
stringency. After each round of panning, 90 individual clones were picked and
inoculated into 2X TY-Amp/Glu and were grown overnight at 37 °C, with shaking
at 220–250 rpm. The next day, these overnight cultures were used to inoculate 2X
TY-Amp and infected with M13 helper phage to obtain populations of monoclonal
VNAR-presenting phage. Enrichment of antigen binding monoclonal phage was
evaluated using a direct antigen-binding ELISA.
ELISA. The 96 wells of F-bottom microtitre plates (Greiner Bio-One) were coated
with 1 µg/mL SARS-CoV-2 RBD protein in PBS, pH 7.4 for 1 h at 37 °C. The plates
were blocked with 4% MPBS, incubated for 1 h at 37 °C. Blocked plates were
washed 3X with PBST (PBS+ 0.1% (v/v) Tween-20) and PBS. Supernatant of
individual monoclonal phage was added to designated wells, incubated for 1 h at
room temperature before washing 3X with PBST and PBS. Binding was detected
using 1:10,000 dilution of anti-M13-horseradish peroxidase (HRP)-conjugated
(Stratech Scientific) prepared in 3% (w/v) MPBST. Anti-SARS-CoV-2 RBD anti-
body CR3022-RB (1 µg/mL). After washing, 100 µL of TMB substrate (Fisher
Scientific) was added, neutralized with 50 µL 1M H2SO4 and absorbance measured
at 450 nm with a microplate absorbance reader.
Production of SARS-CoV-2 VNARs. Individual and unique, by DNA sequence,
positive binders to RBD protein were identified for further characterization. Gly-
cerol stocks of the selected VNAR domains were used to inoculate 2X TY-AG,
incubated at 37 °C for 6–8 h, shaking at 250 rpm. The culture was centrifuged, and
the cell pellet resuspended in fresh Terrific Broth (TB) media supplemented with
phosphate salt, 1% (w/v) glucose and 100 µg/mL ampicillin, incubated overnight at
37 °C at 250 rpm. The overnight culture was centrifuged, re-suspended in fresh TB
media supplemented with phosphate salt, and 100 µg/mL ampicillin, incubated at
25–28 °C, 200 rpm for 1 h. Protein expression was induced for 6 h with a final
concentration of 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) added to
the culture, incubated at 25–28 °C, 200 rpm. After 6 h induction, the culture was
centrifuged and the resulting cell paste was re-suspended with ice-cold 2-[Tris-
(hydroxymethyl)-methylamino]-1-ethane sulfonic acid (TES) by incubation for
15 min at 15–20 °C, on a 100-rpm shaking platform. An equal volume of ice-cold
2.5 mM MgSO4 was added to the culture, and the incubation continued for a
further 15 min. The culture was centrifuged for 30 min, at 4 °C, and the super-
natant carefully collected. The supernatant was filtered through a 0.22 µm filter to
further clarify the protein solution prior to purification via a poly-histidine tag
using immobilized metal affinity chromatography (IMAC). 2C02 used in crystal-
lographic analysis was expressed in SHuffle T7 express E. coli strain (NEB) and
purified using IMAC and size-exclusion chromatography.
Production of pseudotyped viruses. Pseudotyped retroviruses expressing a
luciferase reporter gene were prepared by co-transfecting HEK293T cells with a
plasmid encoding an Env-defective and luciferace-encoding HIV-1 genome (pNL4-
3.luc.R-E-) and a plasmid encoding either SARS-CoV-2 Spike, SARS-CoV-1 Spike,
WIV1-CoV Spike, MERS-CoV Spike, or vesicular stomatitis virus glycoprotein
(VSV-G). Transfections were performed with 15 µg of each plasmid in a 175 cm2
culture flask (Nunc) using Lipofectamine 3000 (Thermo Fisher). Medium-
containing transfection complexes was replaced with fresh complete medium after
8 h. Secreted pseudovirus particles were harvested from HEK293T supernatant 72 h
after transfection. Pseudovirus stocks were stored at −80 °C in single-use aliquots
and were titered using the Reed-Muench method to determine TCID50
concentrations31.
Pseudovirus neutralization assays. Cell infection assays were carried out as
described previously32. HEK293T-hACE2 or Calu-3 cells were used to monitor
pseudovirus infectivity. The day before viral transduction, 1 × 104 HEK293T/ACE2
cells or 5 × 104 Calu-3 cells were plated into each well in 96-well plates (Midwest
Scientific). The day of transduction, 10-fold serial dilutions of VNARs were pre-
pared in a separate 96-well plate in complete medium and supplemented with a
1000xTCID50 dose of pseudovirus per well, the VNAR/pseudovirus mixture was
incubated for 1 h at 37 °C. Media was removed from cultured cells and replaced
with the pre-incubated VNAR/pseudovirus mixture, plates were incubated over-
night at 37 °C and 5% CO2. The following day, cells were washed twice with DPBS
and media was replaced with a complete medium. Three days post-transduction,
cells were assayed for luciferase activity using ONE-Glo Luciferase Assay System
(Promega). Briefly, culture media was partially removed, leaving 50 µl of media/
well, an equal volume of ONE-Glo reagent was added to each well, plates were
incubated for 3 min at room temperature on a microplate shaker, and aliquots from
each well were transferred to a solid white 96-well assay plate (CellStar).
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Luminescence was measured using a Tecan Infinite M1000 microplate reader and
Magellan Standard v7.2 software. Luminescence values are reported relative to
levels measured in cells treated with virus alone, background corrected by lumi-
nescence values in cells unexposed to virus. Samples were tested in technical tri-
plicates across three independent biological experiments. Data were processed in
Microsoft Excel v2110. Concentration-response curves and IC50 values were gen-
erated in OriginLab 2021b.
Authentic SARS-CoV-2 neutralization assays. Vero E6 cells (2.5 × 104) were
seeded in each well of a 96-well black/clear flat bottom TC-treated plate (Falcon)
and incubated in DMEM overnight at 37 °C with 5% CO2 before infection.
Antibody samples were serially diluted in DMEM and incubated with mNeon-
Green SARS-CoV-2 at 37 °C for 1 h33. Medium was removed from cells and the
virus-antibody mixture was added to achieve a final multiplicity of infection of 0.1
plaque-forming units per cell. The cells were incubated at 37 °C with the virus-
antibody mixture for 24 to 26 h. After incubation, cells were fixed in 4% paraf-
ormaldehyde at 4 °C for 30 min. The paraformaldehyde-virus-plasma mixture was
removed, cells were washed once with PBS, and 50 μL of PBS was added to each
well. The fluorescence signal was determined by reading the plates on a Synergy H1
hybrid multimode reader (BioTek) with BioTek Gen5 v2.09.1 software, using
excitation/emission wavelengths of 488/517 nm. Percent maximal infection was
determined for each dilution as the ratio of the fluorescent signal to the maximal
signal for non-treated controls in the same plate. Each sample was tested with two
technical replicates across three independent biological experiments. Data were
processed in Microsoft Excel v2110. Concentration-response curves and IC50
values were generated in OriginLab 2021b.
Biolayer interferometry (BLI). BLI measurements were obtained using a forteBIO
OctetRED96e instrument. Biotinylated S-RBD protein (AcroBiosystems) was
captured on a SAX (high precision streptavidin) biosensor. The SAX biosensors
were hydrated in an assay buffer of PBS containing 0.1% BSA. Hydrated SAX
sensors were equilibrated for 30 s in assay buffer before the S-RBD protein was
loaded for 45 s. Following the bait protein capture a second equilibration step was
performed for 60 s. Serial dilutions of the anti-SARS-CoV-2 VNARs (1:2 dilutions
from 1 µM to 31.25 nM) were injected over the biosensor for 240–300 s followed by
240–300 s dissociation. Two controls were included in each measurement, a no bait
(S-RBD) control was used that was exposed to the 1 µM concentration to ensure
the VNAR did not bind to an empty SAX sensor and a no VNAR control was used
to ensure additional signal on the S-RBD loaded sensor was not non-specific.
Binding affinities were determined by analysis of generated binding curves in the
Octet DataAnalysis v12.0.2.3 software program. The controls were averaged and
subtracted from the data before modeling and the dissociation constant (KD) was
calculated. Figures were generated by plotting data in GraphPad Prism v9.0.
VNAR-RBD crystallization. Purified SARS-CoV-2 RBD and VNARs were mixed at
~1:1 molar ratio and the complex formed was isolated using a Superdex200 size-
exclusion chromatography (SEC) column operating with 10mM Tris-HCl (pH 7.4)
and 150mM NaCl. The isolated complex was concentrated by ultrafiltration to
~11mgml−1 and subjected to crystallization. The RBD-VNAR 3B4 complex was
crystallized by the sitting drop vapor diffusion method, using a reservoir solution
containing 0.2M sodium acetate and 20% (w/v) PEG 3350. The crystals grew to full
size in three days. The RBD-VNAR 3B4 crystals were cryo-protected by brief soaking
in the reservoir solution supplemented with 25% ethylene glycol and flash-cooled by
plunging in liquid nitrogen. X-ray diffraction data were collected at the Advanced
Photon Source NE-CAT beamline 24-ID-C. The RBD-VNAR 2C02 complex was
prepared similarly to the above, except that the NaCl concentration of 200mM was
used in SEC and the isolated complex was concentrated to ~15mgml−1. The RBD-
2C02 complex was crystallized by the sitting drop vapor diffusion method, using a
reservoir solution containing 0.2M sodium sulfate and 20 % (w/v) PEG 3350. The
RBD-2C02 crystals were cryo-protected as above and data collected at the NE-CAT
beamline 24-ID-E. All X-ray diffraction data were processed using XDS version
2021020534. The RBD of the spike protein of SARS-CoV-2 (PDB ID: 6YM0) and
shark IgNAR variable domain (PDB ID: 4HGK) were used as molecular replacement
search models. Molecular replacement calculation using PHASER version 2.8
identified the solution with two copies each of RBD and VNAR 3B4 in the asym-
metric unit35. Iterative manual model building and refinement were done using
COOT version 7766 and PHENIX version v.1.19.2-4158, respectively36,37. The mFo-
DFc map clearly showed the presence of glycans in later stages of the refinement.
The glycan on Asn343 was manually modeled into the mFo-DFc density using
COOT. Molecular replacement for the RBD-2C02 complex was done using the RBD
and VNAR 3B4 portions of the RBD-3B4 structure separately as search models.
Refinement and model building procedures were similar to those for the RBD-
VNAR 3B4 complex. In the RBD-2C02 crystal there is one complex in the asym-
metric unit. The summary of data collection and model refinement statistics is
shown in Supplementary Table 2. The coordinates and structure factors have been
deposited in the Protein Data Bank with the accession code 7SPO and 7SPP.
Sequence alignment and homology modeling. SARS-CoV-1, SARS-CoV-2, and
MERS sequence alignments were generated using published sequence data in the
alignment program Clustal X2. The resulting alignments were used in the “Target-
Template Alignment” tool in the online modeling program, SwissModel. The x-ray
structures of the RBD-VNAR 3B4 and 2C02 complexes were used as templates for
modeling the SARS-CoV-1 and MERS RBD-VNAR complexes. By default, Swiss-
Model will only account for one of the protein chains in a coordinate file and will
not effectively model interactions between residues of multiple chains. To circum-
vent this, coordinate files for the RBD-VNAR complexes were altered in PyMol
version 2.5 to include both protein chains in a single segment and single chain. The
sequence was renumbered in numerical order and thirty amino acids of the pattern
Gly-Ala-Ser were inserted as a spacer between the proteins in the modified
sequence. The modified coordinate file was exported to be used as the template for
the “User Template” tool in SwissModel. Text sequences for SARS-CoV-1 and
MERS RBD-VNAR complexes, organized in a similar fashion as the template
coordinate file and containing the G-A-S insertion, were uploaded and the model
was run. In PyMol, resulting models were then separated into individual chains and
segments and renumbered to match the original coordinate file. Homology of the
modeled RBD-VNAR interactions were compared to the original coordinate files.
Data statistics. All infectivity data represents the mean ± s.e.m. of at least three
independent biological replicates. No data exclusions were made. No randomiza-
tion or blinding measures were made.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The data that support this study are available from the corresponding authors upon
reasonable request. The structural data generated in this study have been deposited in the
RCSB Protein Data Bank. Structures of SARS-CoV-2 RBD in complex with VNAR 3B4
or VNAR 2C02 are original to this work and can be found with accession codes 7SPO
and 7SPP, respectively. Previously reported structures retrieved from PDB: 2AJF, 4L72,
6YM0, 4HGK, 7DF4, and 7BF4. Sequences of lead VNAR antibodies are collated in
Supplementary Table 3. Source data are provided with this paper.
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